1. Taiwan Stocks

  2. •

    Health services

  3. •

    Medical/Nursing services
Tci Gene Inc.

Tci Gene Inc.

TTPEX:6879
36.45
TWD
0.00
(0.00%)
978.97MMarket Cap
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
10.23
10.47
22.62
17.32
12.62
13.14
10.34
- -
Basic EPS, GAAP
3.07
1.94
4.84
2.95
0.44
2.13
1.53
- -
Free Cash Flow per Basic Share
4.76
1.72
5.01
3.88
0.55
2.05
5.7
- -
Dividend per Share
- -
- -
- -
2.19
2
1
2
- -
Book Value per Share
6.51
7.86
14.37
37.99
37.29
36.84
33.66
34.56
Tangible Book Value per Share
6.08
7.53
14.15
37.75
37.07
36.67
33.52
34.44
Basic Weighted Avg Shares
18
18
19
24
26
26
26
26
Sales/Revenue/Turnover
189
193
432
424
334
348
274
- -
Operating Margin (%)
29.83
24.13
26.28
21.48
1.8
16.05
6.97
- -
Depreciation Expense
6
7
38
30
16
14
12
- -
Net Income, GAAP
57
36
92
72
12
56
41
- -
Effective Tax Rate (%)
1.52
25.32
20.86
17.52
- -
16.33
- -
- -
Profit Margin (%)
30
18.53
21.39
17.01
3.5
16.2
14.83
- -
Working Capital
139
160
317
933
913
893
816
849
LT Debt
- -
- -
- -
- -
- -
- -
- -
- -
Total Equity
180
216
391
1,020
1,010
998
913
937
Return on Invested Capital (%)
- -
17.1
27.6
10.18
- -
4.31
- -
- -
Return on Capital (%)
- -
17.99
30.36
9.94
- -
5.61
- -
- -
Return on Common Equity (%)
- -
18.81
31.44
10.42
1.17
5.74
4.35
- -

Capital Structure

TWD

•

in mil. unless spec.
Jun'25
Dec'25
Jun'26
ST Debt
11
7
4
LT Borrowings
- -
- -
- -
LT Finance Leases
3
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
26
26
26
Market Capitalization
1,103
939
979

Working Capital

TWD

•

in mil. unless spec.
Jun'25
Dec'25
Jun'26
Total Current Assets
1,005
914
962
Cash, Cash Equivalents & STI
887
832
859
Accounts Receivable, Net
74
44
60
Inventories
31
19
20
Total Current Liabilities
175
99
113
Payables & Accruals
- -
- -
- -
ST Debt
11
7
4
Deferred Revenue
- -
- -
- -

Growth Rates

TWD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
46.31%
-8.53%
Free Cash Flow
- -
112.87%
177.91%
Net Income, GAAP
- -
81.46%
-27.96%
Sales/Revenue/Turnover
- -
16.74%
-21.27%
Total Cash Common Dividend
- -
- -
100%

Semi-annual Revenue

TWD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
348
2025
- -
- -
274
2026
- -
- -
- -

Semi-annual Earnings Per Share

TWD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
2.13
2025
- -
- -
1.53
2026
- -
- -
- -

Semi-annual Dividends Per Share

TWD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
1
2025
- -
- -
2
2026
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Ji Lun Wu
Full Time Employees
50
Sector
Health services
Industry
Medical/Nursing services
Address
No. 185 Gangchen Road Taipei TP Taiwan 11494
IPO Date
Jan 25, 2022
Website
genext.me
Similar Companies
Hims & Hers Health, Inc. (NYSE:HIMS)
Ginkgo Bioworks Holdings, Inc. (NYSE:DNA)
Mobile-health Network Solutions (NASDAQ:MNDR)
Dr. Lal PathLabs Limited (NSE:LALPATHLAB)
Tenon Medical, Inc. (NASDAQ:TNON)
Teladoc Health, Inc. (NYSE:TDOC)
Business
TCI GENE Inc. (6879.TWO) provides precision preventive medicine solutions, including genetic testing and related health products, primarily in Taiwan. Founded in 2019 as a subsidiary of TCI Co., Ltd., the company is headquartered at No. 185 Gangchen Road, 10th Floor, Taipei, Taiwan, and listed on the Taipei Exchange in January 2022. It operates within the biotechnology and healthcare services sectors, targeting consumers seeking personalized health management through genetic insights and nutrition consultation services. The company offers genetic testing for nutrient metabolism and weight management; G2 and ACE2 genetic testing; supplements; skin care products; anti-aging solutions; kids' growth products; Alzheimer disease products; and serum tailored to DNA types. TCI GENE provides comprehensive precision medicine solutions encompassing preventive testing, disease treatment, and postoperative care, integrating genetic testing with cell therapy, tissue engineering, and human organ applications. Its services leverage advanced genetic technologies to assess individual constitutions and deliver customized health outcomes. In 2022, Qisda Corp. acquired a 17.84% stake in TCI GENE through a private placement valued at NT$545.16 million, forming a strategic alliance to expand biotechnology and precision medicine offerings by combining resources in genetic testing, medical services, equipment, and big data solutions. As part of the TCI Group, which evolved into a CDMO+ model in 2025 with AI-driven innovations for regulatory support and supply chain management, TCI GENE benefits from group-wide expansions including subsidiaries like TCI Living and MBI. The company maintains operations focused on Taiwan while supporting the group's presence across Asia, North America, and Europe.